FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022256466> ?p ?o ?g. }

• W2022256466 endingPage "336.e1" @default.
• W2022256466 startingPage "328" @default.
• W2022256466 abstract "Purpose To investigate the influence of vitreomacular adhesion on the efficacy of pro re nata (PRN) ranibizumab monotherapy and verteporfin photodynamic therapy (PDT) combination therapy for neovascular age-related macular degeneration. Design Post hoc analysis of prospective randomized 12-month multicenter clinical trial data. Methods patient population: Total of 255 treatment-naïve patients with subfoveal choroidal neovascularization. observation procedure: Assessment of the vitreomacular interface on monthly optical coherence tomography with division of patients into the following categories according to continuous 1-year grading: posterior vitreous detachment (n = 154), dynamic release of vitreomacular adhesion (n = 32), stable vitreomacular adhesion (n = 51). main outcome measures: Mean best-corrected visual acuity (BCVA) letter and central retinal thickness changes at month 12 in the vitreomacular interface groups. Results Mean BCVA changes at month 12 were +3.5 (posterior vitreous detachment), +4.3 (release of vitreomacular adhesion), and +6.3 (vitreomacular adhesion) in patients receiving monotherapy (P = .767), and +0.1 (posterior vitreous detachment), +6.6 (release of vitreomacular adhesion), and +9.2 (vitreomacular adhesion) in patients receiving combination therapy (P = .009). Mean central retinal thickness changes were −113 μm (posterior vitreous detachment), −89 μm (release of vitreomacular adhesion), and −122 μm (vitreomacular adhesion) in monotherapy (P = .725) and −121 μm (posterior vitreous detachment), −113 μm (release of vitreomacular adhesion), and −113 μm (vitreomacular adhesion) in combination therapy (P = .924). Mean ranibizumab retreatments during 12 months were 4.9 (posterior vitreous detachment), 6.6 (release of vitreomacular adhesion), and 5.3 (vitreomacular adhesion) in monotherapy (P = .018) and 4.7 (posterior vitreous detachment), 5.2 (release of vitreomacular adhesion), and 5.8 (vitreomacular adhesion) in combination therapy (P = .942). Conclusion This study adds evidence that the vitreomacular interface status impacts functional outcomes and retreatment requirements. Patients with posterior vitreous detachment achieve acceptable results with fewer injections in PRN monotherapy, but lose potential vision gain with PDT. Patients with other vitreomacular interface configurations may potentially achieve optimized vision outcomes by combination of antiangiogenic treatment and vaso-occlusive PDT. To investigate the influence of vitreomacular adhesion on the efficacy of pro re nata (PRN) ranibizumab monotherapy and verteporfin photodynamic therapy (PDT) combination therapy for neovascular age-related macular degeneration. Post hoc analysis of prospective randomized 12-month multicenter clinical trial data. patient population: Total of 255 treatment-naïve patients with subfoveal choroidal neovascularization. observation procedure: Assessment of the vitreomacular interface on monthly optical coherence tomography with division of patients into the following categories according to continuous 1-year grading: posterior vitreous detachment (n = 154), dynamic release of vitreomacular adhesion (n = 32), stable vitreomacular adhesion (n = 51). main outcome measures: Mean best-corrected visual acuity (BCVA) letter and central retinal thickness changes at month 12 in the vitreomacular interface groups. Mean BCVA changes at month 12 were +3.5 (posterior vitreous detachment), +4.3 (release of vitreomacular adhesion), and +6.3 (vitreomacular adhesion) in patients receiving monotherapy (P = .767), and +0.1 (posterior vitreous detachment), +6.6 (release of vitreomacular adhesion), and +9.2 (vitreomacular adhesion) in patients receiving combination therapy (P = .009). Mean central retinal thickness changes were −113 μm (posterior vitreous detachment), −89 μm (release of vitreomacular adhesion), and −122 μm (vitreomacular adhesion) in monotherapy (P = .725) and −121 μm (posterior vitreous detachment), −113 μm (release of vitreomacular adhesion), and −113 μm (vitreomacular adhesion) in combination therapy (P = .924). Mean ranibizumab retreatments during 12 months were 4.9 (posterior vitreous detachment), 6.6 (release of vitreomacular adhesion), and 5.3 (vitreomacular adhesion) in monotherapy (P = .018) and 4.7 (posterior vitreous detachment), 5.2 (release of vitreomacular adhesion), and 5.8 (vitreomacular adhesion) in combination therapy (P = .942). This study adds evidence that the vitreomacular interface status impacts functional outcomes and retreatment requirements. Patients with posterior vitreous detachment achieve acceptable results with fewer injections in PRN monotherapy, but lose potential vision gain with PDT. Patients with other vitreomacular interface configurations may potentially achieve optimized vision outcomes by combination of antiangiogenic treatment and vaso-occlusive PDT." @default.
• W2022256466 created "2016-06-24" @default.
• W2022256466 creator A5005634785 @default.
• W2022256466 creator A5013612641 @default.
• W2022256466 creator A5053271086 @default.
• W2022256466 creator A5053563726 @default.
• W2022256466 creator A5082511433 @default.
• W2022256466 creator A5090227675 @default.
• W2022256466 date "2014-08-01" @default.
• W2022256466 modified "2023-10-17" @default.
• W2022256466 title "Impact of Vitreomacular Adhesion on Ranibizumab Mono- and Combination Therapy for Neovascular Age-Related Macular Degeneration" @default.
• W2022256466 cites W1481978003 @default.
• W2022256466 cites W1500728559 @default.
• W2022256466 cites W1973249004 @default.
• W2022256466 cites W1975730266 @default.
• W2022256466 cites W1976433015 @default.
• W2022256466 cites W1979981959 @default.
• W2022256466 cites W1982733715 @default.
• W2022256466 cites W1982978147 @default.
• W2022256466 cites W2003324689 @default.
• W2022256466 cites W2007565584 @default.
• W2022256466 cites W2017262248 @default.
• W2022256466 cites W2023343217 @default.
• W2022256466 cites W2024848735 @default.
• W2022256466 cites W2042321005 @default.
• W2022256466 cites W2045317893 @default.
• W2022256466 cites W2050164779 @default.
• W2022256466 cites W2079353692 @default.
• W2022256466 cites W2085712747 @default.
• W2022256466 cites W2091989599 @default.
• W2022256466 cites W2100599719 @default.
• W2022256466 cites W2124415048 @default.
• W2022256466 cites W2125419158 @default.
• W2022256466 cites W2135936686 @default.
• W2022256466 cites W2138388470 @default.
• W2022256466 cites W2138630406 @default.
• W2022256466 cites W2146673937 @default.
• W2022256466 cites W2149277339 @default.
• W2022256466 cites W2154073405 @default.
• W2022256466 cites W2162096507 @default.
• W2022256466 cites W2274897602 @default.
• W2022256466 cites W2312502049 @default.
• W2022256466 cites W2766004112 @default.
• W2022256466 cites W4247214019 @default.
• W2022256466 cites W45051902 @default.
• W2022256466 cites W945208301 @default.
• W2022256466 doi "https://doi.org/10.1016/j.ajo.2014.04.028" @default.
• W2022256466 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24794282" @default.
• W2022256466 hasPublicationYear "2014" @default.
• W2022256466 type Work @default.
• W2022256466 sameAs 2022256466 @default.
• W2022256466 citedByCount "32" @default.
• W2022256466 countsByYear W20222564662015 @default.
• W2022256466 countsByYear W20222564662016 @default.
• W2022256466 countsByYear W20222564662017 @default.
• W2022256466 countsByYear W20222564662018 @default.
• W2022256466 countsByYear W20222564662019 @default.
• W2022256466 countsByYear W20222564662020 @default.
• W2022256466 countsByYear W20222564662021 @default.
• W2022256466 countsByYear W20222564662022 @default.
• W2022256466 countsByYear W20222564662023 @default.
• W2022256466 crossrefType "journal-article" @default.
• W2022256466 hasAuthorship W2022256466A5005634785 @default.
• W2022256466 hasAuthorship W2022256466A5013612641 @default.
• W2022256466 hasAuthorship W2022256466A5053271086 @default.
• W2022256466 hasAuthorship W2022256466A5053563726 @default.
• W2022256466 hasAuthorship W2022256466A5082511433 @default.
• W2022256466 hasAuthorship W2022256466A5090227675 @default.
• W2022256466 hasConcept C118487528 @default.
• W2022256466 hasConcept C141071460 @default.
• W2022256466 hasConcept C178790620 @default.
• W2022256466 hasConcept C185592680 @default.
• W2022256466 hasConcept C2776403814 @default.
• W2022256466 hasConcept C2776694085 @default.
• W2022256466 hasConcept C2777802072 @default.
• W2022256466 hasConcept C2778257484 @default.
• W2022256466 hasConcept C2779676219 @default.
• W2022256466 hasConcept C2781100027 @default.
• W2022256466 hasConcept C2781148688 @default.
• W2022256466 hasConcept C2781242345 @default.
• W2022256466 hasConcept C2781359195 @default.
• W2022256466 hasConcept C71924100 @default.
• W2022256466 hasConcept C84416704 @default.
• W2022256466 hasConceptScore W2022256466C118487528 @default.
• W2022256466 hasConceptScore W2022256466C141071460 @default.
• W2022256466 hasConceptScore W2022256466C178790620 @default.
• W2022256466 hasConceptScore W2022256466C185592680 @default.
• W2022256466 hasConceptScore W2022256466C2776403814 @default.
• W2022256466 hasConceptScore W2022256466C2776694085 @default.
• W2022256466 hasConceptScore W2022256466C2777802072 @default.
• W2022256466 hasConceptScore W2022256466C2778257484 @default.
• W2022256466 hasConceptScore W2022256466C2779676219 @default.
• W2022256466 hasConceptScore W2022256466C2781100027 @default.
• W2022256466 hasConceptScore W2022256466C2781148688 @default.
• W2022256466 hasConceptScore W2022256466C2781242345 @default.
• W2022256466 hasConceptScore W2022256466C2781359195 @default.
• W2022256466 hasConceptScore W2022256466C71924100 @default.
• W2022256466 hasConceptScore W2022256466C84416704 @default.

• next